New generations of targeted therapies fighting the resistance in solid tumors
Philippe Barthélémy1, Philippe Aftimos, Ahmad Awada
1aMedical Oncology Clinic, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium bDépartement d'Oncologie médicale et d'hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Purpose Of Review:
The identification of molecular alterations that drive tumor growth and spread of solid tumors has led to the development of multiple targeted therapies considered as first-generation agents that have improved clinical benefit. However, tumor cells are able to rapidly develop resistance to these agents. The growing understanding of the biology of the resistance mechanisms has spurred ongoing development of second-generation and third-generation targeted therapies aiming at new strategies to overcome resistance.
Recent Findings:
Several generations of targeted therapies have been developed in order to prevent, delay or overcome tumor resistance. Some agents have already been approved, and others are currently under active clinical investigation in several cancer subtypes, including breast cancer, nonsmall cell lung cancer, head and neck squamous cell cancer and colorectal cancer.
Summary:
In the present review, we will discuss in solid tumors, the recent development of next generation anticancer-targeted therapies and new strategies including combination agents currently under active clinical investigation.
Insights
Next-generation targeted therapies are being developed to overcome resistance in solid tumors. These advanced treatments, including combination agents, are crucial for improving patient outcomes in various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted therapies have improved solid tumor treatment by targeting molecular alterations.
- Tumor cells frequently develop resistance to first-generation targeted agents.
- Understanding resistance mechanisms drives the development of novel therapeutic strategies.
Purpose of the Study:
- To review the development of next-generation targeted therapies for solid tumors.
- To discuss strategies for overcoming therapeutic resistance.
- To highlight agents under active clinical investigation.
Main Methods:
- Review of current literature on targeted cancer therapies.
- Analysis of resistance mechanisms in solid tumors.
- Examination of clinical trial data for next-generation agents.
Main Results:
- Multiple generations of targeted therapies have been developed to combat tumor resistance.
- Several novel agents are approved or in clinical trials for various cancers.
- Combination therapies are emerging as a key strategy.
Conclusions:
- Next-generation targeted therapies represent a significant advancement in cancer treatment.
- Ongoing research focuses on overcoming resistance and improving efficacy.
- Clinical investigation is essential for validating new therapeutic approaches.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
09:12Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy